The cannabis industry has no doubt taken on a life of its own in recent years. Now that legalization is taking shape at a federal level–at least in Canada–the tide has officially begun turning for growing sector.
On April 13, the Canadian federal government finally announced its much anticipated bill to legalize recreational use of cannabis by July 2018. In particular, the bill follows many of the recommendations made in the federal task force, released in late 2016.
Indeed, Canada’s decision to legalize marijuana recreationally certainly sets the framework for other countries around the world following suite. In fact, Canada is the first developed country to fully legalize marijuana since the war on drugs started in the 1970s. Uruguay is the only other country in the world that allows recreational use of marijuana.
With that in mind, here’s a look at some of the rules surrounding legalizing marijuana in Canada–and if the US will be the next to do so.

Legalizing marijuana: Canada a go

As mentioned above, the framework for legalizing marijuana in Canada will follow a number of the recommendations made in the task force released in November, 2016. This also means significant policy changes for Canadian public health and safety.
The bills, introduced in the House of Commons by Justice Minister Jody Wilson-Raybould, Public Safety Minister Ralph Goodale, Health Minister Jane Philpott, and Foreign Affairs Minister Chrystia Freeland, first establishes a minimum age of 18 years old to purchase marijuana.
Of course, laws surrounding framework for production, sales, distribution and possession of marijuana are also part of the suite of bills: individuals over the age of 18 will be able to possess up to 30 grams of dried marijuana, or its equivalent, in public settings.  Residents will be able to grow up to four plants per home, in addition to making legal-cannabis products.
The federal government has also propositioned a change to the Criminal Code to punish those who attempt to provide youth under the age of 18 with marijuana, or sell it outside of the new legal regulations.
The Globe and Mail stated that the legislation would put in place new criminal offences, including a maximum penalty of 14 years to anyone who sells or provides marijuana to a minor.
On that note, there are currently 42 companies that have been authorized by Health Canada to produce medicinal marijuana across the country. The Globe and Mail wrote that the federal government will need additional staff and resources to “speed up the approval process” for new producers looking to come online.
With that in mind, the world’s first cannabis ETF was launched in Canada in early April. Horizons ETF Management inaugurated the Horizons Medical Marijuana Life Sciences (TSX:HMMJ) on the Toronto Stock Exchange, with 14 marijuana stocks included in the fund, at least for now.
Indeed, there’s plenty to look forward to with legalizing marijuana in Canada, and new companies will no doubt be chomping at the bit to get in on the action.


Legalizing marijuana: is the US next?

Down in the US, however, laws for recreational cannabis in the US are still a work in progress. That said, it is legal in eight states while 28 have some form of medical marijuana. Even though cannabis remains illegal at a federal law, Canada’s legalization could very well be the push the US needs to follow in the same steps.
That said, it is important for investors to understand the legalities surrounding the medical cannabis and hemp industries. One key point is that regulations in Canada and the US differ from the municipal, provincial and state levels to the federal level.
Despite having low levels of mind-altering THC, hemp has been lumped into the same category as marijuana in the US, and is classified as a Schedule 1 drug under the Controlled Substances Act. Previously, the US allowed patients with a variety of medical conditions to smoke marijuana in a variety of states since 1996, and four states have voted to allow the sale and distribution of marijuana. However, that number is now growing.
Still, under a Donald Trump presidency, the laws are still murky: there’s no signs indicating that will happen any time soon.
Don’t forget to follow us @INN_Resource for real-time news updates.
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article. 

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less